Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Lung Cancer

Free Subscription 14.09.2026 2 Am J Clin Oncol 1 Am J Respir Crit Care Med 1 Ann Surg Oncol 1 BMC Cancer 1 Cancer 1 Cancer Epidemiol Biomarkers Prev 1 Cancer Sci 2 Chest 2 Clin Cancer Res 7 Clin Lung Cancer 2 Clin Nucl Med 1 Eur Respir J 1 Genes Chromosomes Cancer 1 Hum Pathol 3 Int J Cancer 1 Int J Radiat Oncol Biol Phys 1 J Immunol 2 Lancet 1 Lancet Oncol 13 Lung Cancer 1 Lung Cancer (Auckl) 1 Mol Carcinog 2 N Engl J Med 1 Nat Genet 1 Oncol Rep 1 PLoS One 1 Semin Oncol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Clin Oncol

1. AMIR E, Khan MW, Mannan MS, Rayyan SM, et al
   Efficacy and Safety of Savolitinib Plus Osimertinib in EGFR-Mutant, MET-Aberrant Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
   Am J Clin Oncol. 2026 Sep 7. doi: 10.1097/COC.0000000000001367.
   PubMed         Abstract available
   
   
2. ALBALAWI HA
   From Correlation to Clinical Translation: The Biological-GroundingxTranslational-Readiness Framework for Artificial Intelligence in Non-Small-Cell Lung Cancer.
   Am J Clin Oncol. 2026 Sep 7. doi: 10.1097/COC.0000000000001370.
   PubMed         Abstract available
   
   

   
   Am J Respir Crit Care Med

3. MURPHY NR, Triplette M, Adams SV, Rustagi AS, et al
   Outcomes of lung cancer screening in a nation-wide cohort of people with HIV compared to without HIV.
   Am J Respir Crit Care Med. 2026 Sep 10:aamag448. doi: 10.1093.
   PubMed        
   
   

   
   Ann Surg Oncol

4. MAN L, Hao X, Zhang X, Cheng J, et al
   Prognostic Impact of Lymphovascular Invasion in Resected Pathological Stage I Invasive Non-small Cell Lung Cancer: A Propensity Score-Matched Cohort Study.
   Ann Surg Oncol. 2026 Sep 7. doi: 10.1245/s10434-026-20467.
   PubMed         Abstract available
   
   

   
   BMC Cancer

5. ZENG J, Wei L, Chen H, Liang Y, et al
   Habitat model based on CEUS for noninvasive prediction of EGFR mutation status in peripheral NSCLC.
   BMC Cancer. 2026;26:1080.
   PubMed         Abstract available
   
   

   
   Cancer

6. COOPER AJ, Sands J
   T-cell engagers in small cell lung cancer.
   Cancer. 2026;132:e70600.
   PubMed         Abstract available
   
   

   
   Cancer Epidemiol Biomarkers Prev

7. FAN Q, Xu M, Katana Ogongo M, Hu X, et al
   Association of Area-level Broadband Access and Non-Small Cell Lung Cancer Diagnosis and Guideline-Concordant Care in the US.
   Cancer Epidemiol Biomarkers Prev. 2026.
   PubMed         Abstract available
   
   

   
   Cancer Sci

8. YANG J, Xiong J, Ying L, Zeng Y, et al
   Lung Cancer Brain Metastasis: Brain Microenvironmental Adaptation, Therapeutic Resistance and Translational Strategies.
   Cancer Sci. 2026 Sep 10. doi: 10.1111/cas.70527.
   PubMed         Abstract available
   
   

   
   Chest

9. LIANG YD, Meng WQ, Wang YX, Gu T, et al
   A 40-Year-Old Woman With Exertional Dyspnea and Unexplained Hypoxia.
   Chest. 2026;170:e91-e95.
   PubMed         Abstract available
   
   
10. PROSPER AE, Kammer MN
    Without (Estimation of Lung Cancer) Risk, There Is No Reward.
    Chest. 2026;170:667-668.
    PubMed        
    
    

    
    Clin Cancer Res

11. LI D, Garon EB
    Lessons from Cohort Studies of Targetable Metabolic Deficiencies in Lung Cancer.
    Clin Cancer Res. 2026 Sep 11. doi: 10.1158/1078-0432.CCR-26-2458.
    PubMed         Abstract available
    
    
12. MIDDLETON G, Buchanan R, Savage J, De La Mata Chicharro J, et al
    Ceralasertib plus durvalumab in Ras mutant and Ras wild type advanced non-small cell lung cancer: Two cohorts of the phase II platform National Lung Matrix Trial.
    Clin Cancer Res. 2026 Sep 9. doi: 10.1158/1078-0432.CCR-26-1365.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

13. LELIVELD A, Willems B, Balbi M, Capelletto E, et al
    PINPOINT: Integrating Computer Assisted Detection and Virtual Nodule Clinics for Early Lung Cancer Detection in Routine Practice, A Pilot Study.
    Clin Lung Cancer. 2026;27:44-49.
    PubMed         Abstract available
    
    
14. RIEDEL R, Verheyen M, Michels S, Ruge L, et al
    Rationale and Study Design of the GUIDANCE trial: A Multicenter Phase II Trial of Maintenance Durvalumab and Olaparib After Standard Fist Line Treatment (Carboplatin/Cisplatin, Etoposide, and Durvalumab) in HRD Positive Extensive Disease (ED) Small-ce
    Clin Lung Cancer. 2026;27:38-43.
    PubMed         Abstract available
    
    
15. CHANG JY, Kelekar G, Miyakawa-Liu M, Wakelee HA, et al
    Prolonged Disease Control on Tepotinib in a Patient With HLA-DRB1-MET-Positive Metastatic Non-small Cell Lung Cancer: The Role of RNA Sequencing and Targeted Therapy for Rare MET Rearrangements.
    Clin Lung Cancer. 2026;27:33-37.
    PubMed        
    
    
16. LUO SS, Zhong LQ, Liu X, Li SN, et al
    Clinical Efficacy and Safety of Icotinib as Adjuvant Therapy for Resected Stage IA Lung Adenocarcinoma: A Real-world Study.
    Clin Lung Cancer. 2026;27:118-124.
    PubMed         Abstract available
    
    
17. ALNAJAR A, Nguyen B, Villamizar N, Nguyen DM, et al
    Impact of Zip-Based Social Determinants on Textbook Outcomes and Survival of Resected Early-Stage NSCLC.
    Clin Lung Cancer. 2026;27:78-86.
    PubMed         Abstract available
    
    
18. NOTSUDA H, Suzuki Y, Onodera K, Kumata S, et al
    Semiconductor FDG PET/CT for Preoperative Identification of Grade 3 Invasive Nonmucinous Adenocarcinoma.
    Clin Lung Cancer. 2026;27:68-77.
    PubMed         Abstract available
    
    
19. BARSOUK AA, Yaskolko M, Sussman JH, Sun L, et al
    Poor Performance Status Associated With Inferior Tarlatamab Outcomes in a Large, Multi-institution Real-World Database of Patients With 2L + ES-SCLC.
    Clin Lung Cancer. 2026;27:50-55.
    PubMed         Abstract available
    
    

    
    Clin Nucl Med

20. ZHANG X, Zhang B, Huang Z, Chen D, et al
    Intrapulmonary Myelolipoma Depicted by 18F-FDG PET/CT.
    Clin Nucl Med. 2026 Jul 20. doi: 10.1097/RLU.0000000000006626.
    PubMed         Abstract available
    
    
21. USMANI S, Elshafie O, Jain A, Al Rawahi A, et al
    68Ga-DOTATOC PET/CT in the Evaluation of Carney Triad Spectrum Tumors With an Associated Adrenal Adenoma.
    Clin Nucl Med. 2026 May 12. doi: 10.1097/RLU.0000000000006544.
    PubMed         Abstract available
    
    

    
    Eur Respir J

22. NOORDHOF AL, Damhuis RAM, Blyth KG, van Schil PE, et al
    Prognostic implication of malignant pleural metastases in stage M1a non-small cell lung cancer in a real-world Dutch cohort receiving chemotherapy and/or immunotherapy.
    Eur Respir J. 2026 Sep 7:2600555. doi: 10.1183/13993003.00555-2026.
    PubMed         Abstract available
    
    

    
    Genes Chromosomes Cancer

23. KOYLU B, Genc NI, Yucel MH, Yildiz A, et al
    Clinicopathologic Features of NRG1 Fusion-Positive Non-Small Cell Lung Cancer.
    Genes Chromosomes Cancer. 2026;65:e70170.
    PubMed         Abstract available
    
    

    
    Hum Pathol

24. JI SF, Law ME, Dawley JC, Manchen PJ, et al
    GPNMB immunohistochemistry distinguishes diagnostically challenging cases of lymphangioleiomyomatosis from other mesenchymal neoplasms presenting with cystic lung metastases.
    Hum Pathol. 2026;176:106192.
    PubMed         Abstract available
    
    

    
    Int J Cancer

25. YANG F, Qiu X, Wang W, Wang Y, et al
    Integrating Plasma Proteomics and Polygenic Risk Scores for the Prediction of Lung Cancer Risk.
    Int J Cancer. 2026 Sep 7. doi: 10.1002/ijc.70710.
    PubMed         Abstract available
    
    
26. HANASH S
    Lung Cancer Risk Assessment Beyond Smoking History.
    Int J Cancer. 2026 Sep 7. doi: 10.1002/ijc.70713.
    PubMed        
    
    
27. TAKAMORI S, Naito T, Konishi N, Tsuji T, et al
    Perioperative Rehabilitation and Initiation of Adjuvant Chemotherapy in Resected Non-Small Cell Lung Cancer.
    Int J Cancer. 2026 Sep 10. doi: 10.1002/ijc.70709.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

28. LIN SH, Pugh SL, Valle DMD, Roudko V, et al
    Safety and Biomarker Analysis of NRG-LU004: Phase I Trial of Accelerated or Conventionally Fractionated Radiotherapy Combined With Durvalumab in PD-L1 High Locally Advanced Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2026 Sep 12:S0360-3016(26)04286.
    PubMed         Abstract available
    
    

    
    J Immunol

29. GUO K, Hu H, Yao N, Zhao Q, et al
    Selenium serves as an immunomodulator adjunct to enhance the efficacy of anti-PD-1 therapy in non-small cell lung cancer.
    J Immunol. 2026;215:vkag241.
    PubMed         Abstract available
    
    

    
    Lancet

30. ROSS JS, Hockemeyer KG, Redin E, Rudin CM, et al
    The changing therapeutic landscape of small-cell lung cancer.
    Lancet. 2026;408:1041-1057.
    PubMed         Abstract available
    
    
31. DALY ME, Simone CB 2nd, Redman MW, Hsieh MH, et al
    Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled tria
    Lancet. 2026 Sep 6:S0140-6736(26)01655-7. doi: 10.1016/S0140-6736(26)01655.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

32. HASSING MJ, Billingy NE, van den Hurk CJG, van den Heuvel MM, et al
    Patient-reported symptom monitoring in patients with lung cancer (SYMPRO-Lung trial): long-term, post-hoc survival results of a multicentre, stepped-wedged, cluster-randomised clinical trial.
    Lancet Oncol. 2026 Sep 11:S1470-2045(26)00305.
    PubMed         Abstract available
    
    

    
    Lung Cancer

33. IMABAYASHI T, Hashimoto H, Takahashi Y, Shionoya I, et al
    Macroscopic on-site evaluation for stratifying the incremental diagnostic benefit of additional sampling during endobronchial ultrasound-guided transbronchial needle aspiration.
    Lung Cancer. 2026;220:109567.
    PubMed         Abstract available
    
    
34. MASFARRE L, Parreira AS, Castro N, Miquel C, et al
    Clinical outcomes of KRAS G12C versus non-G12C mutant NSCLC treated with immunotherapy: a multicentre real-world study.
    Lung Cancer. 2026;220:109560.
    PubMed         Abstract available
    
    
35. DAI K, Cheng S, Wu C, Wang Y, et al
    Distinct spatial immune microenvironment features of different EGFR mutation subtypes in early-stage lung adenocarcinoma.
    Lung Cancer. 2026;220:109562.
    PubMed         Abstract available
    
    
36. SOO RA, Han JY, Ho JC, Ng CSH, et al
    Biology, detection, and management of incidental pulmonary nodules: the emerging role of targeted treatments. A review of the current literature and future perspectives.
    Lung Cancer. 2026;220:109558.
    PubMed         Abstract available
    
    
37. GRAY JE, Thoele K, Richey M, Boualam N, et al
    Therapeutic evolution: Adoption of newly approved systemic therapies in resected stage IB-IIIA NSCLC in the United States.
    Lung Cancer. 2026;220:109586.
    PubMed         Abstract available
    
    
38. YANNOUTSOS A, Pastre J, Damotte D, Percheron V, et al
    Combined low-dose thoracic computed tomography and circulating tumor cell screening for cancer in ever smokers with peripheral arterial disease: A prospective multicenter cohort study.
    Lung Cancer. 2026;220:109587.
    PubMed         Abstract available
    
    
39. DEMIR N, Kikili CI, Kemik F, Koylu B, et al
    Adding immunotherapy to chemotherapy may improve survival after SCLC transformation in EGFR-mutant NSCLC: a multicenter real-world study.
    Lung Cancer. 2026;220:109590.
    PubMed         Abstract available
    
    
40. HARDAVELLA G, Sochorova D, Frille A, Karampinis I, et al
    Large cell neuroendocrine carcinoma of the lung: Current standards, emerging targets, and translational foundations.
    Lung Cancer. 2026;220:109603.
    PubMed         Abstract available
    
    
41. SEKAR P, Kumar AA, Hughes I, Mason R, et al
    Corrigendum to "The safety of extended dosing pembrolizumab when compared to traditional dosing: a review and meta-analysis of retrospective studies" [Lung Cancer 204 (2025) 108585].
    Lung Cancer. 2026 Sep 5:109598. doi: 10.1016/j.lungcan.2026.109598.
    PubMed        
    
    
42. SCHULZ C, Swart S, Muller K, Bernhardt D, et al
    Non-small cell lung cancer with synchronous oligometastatic disease at the time of initial diagnosis. Impact of multimodal treatment on prognosis.
    Lung Cancer. 2026;221:109584.
    PubMed         Abstract available
    
    
43. CURTO D, Hernandez S, Alonso M, Peressini M, et al
    Artificial Intelligence-Based Assessment of Pathologic Response to Neoadjuvant Chemoimmunotherapy in Non-Small Cell Lung Cancer: An International Multicenter Cohort Study.
    Lung Cancer. 2026;221:109609.
    PubMed         Abstract available
    
    
44. EIJKELBOOM AH, Peters BJM, Dumoulin DW, Schramel FMNH, et al
    Treatment-free interval as a determinant of second-line chemotherapy outcomes in extensive-stage small cell lung cancer: a Dutch population-based study.
    Lung Cancer. 2026;221:109621.
    PubMed         Abstract available
    
    
45. WEI Y, Jin R, Liu X, Wang W, et al
    The efficacy and feasibility of neoadjuvant immunochemotherapy versus chemotherapy in Limited-Stage Small-Cell lung cancer.
    Lung Cancer. 2026;221:109607.
    PubMed         Abstract available
    
    

    
    Lung Cancer (Auckl)

46. TIAN Q, Zhang F, Han C
    Identification of JAML as an Immune-Associated Prognostic Marker in Non-Small Cell Lung Cancer.
    Lung Cancer (Auckl). 2026;17:616193.
    PubMed         Abstract available
    
    

    
    Mol Carcinog

47. TENG Y, Cao J, Lei S, Li D, et al
    MELTF Drives Lung Cancer Progression and Angiogenesis via HIF-1alpha-Mediated Activation of the VEGF Signaling Pathway.
    Mol Carcinog. 2026 Sep 8. doi: 10.1002/mc.70173.
    PubMed         Abstract available
    
    

    
    N Engl J Med

48. PEDABALLE KS
    Zongertinib in HER2-Mutant Non-Small-Cell Lung Cancer.
    N Engl J Med. 2026;395:1037-1038.
    PubMed        
    
    
49. HEYMACH JV
    Zongertinib in HER2-Mutant Non-Small-Cell Lung Cancer. Reply.
    N Engl J Med. 2026;395:1038.
    PubMed        
    
    

    
    Nat Genet

50. JONES MG, Sun D, Min KHJ, Colgan WN, et al
    Spatiotemporal lineage tracing reveals the dynamic spatial architecture of tumor growth and metastasis.
    Nat Genet. 2026;58:2398-2410.
    PubMed         Abstract available
    
    

    
    Oncol Rep

51. WU S, Zhang W
    Effect of EZH2 regulation of the JAK2/STAT3 signaling pathway on proliferation and apoptosis in non?small cell lung cancer cells.
    Oncol Rep. 2026;56:184.
    PubMed         Abstract available
    
    

    
    PLoS One

52. ZHENG D, Gao H, Zou Y, Shao Q, et al
    A Latent profile and network intervention analysis of psychosomatic symptoms in lung cancer immunotherapy patients.
    PLoS One. 2026;21:e0357460.
    PubMed         Abstract available
    
    

    
    Semin Oncol

53. CONARD R, Trivedi C, Page W
    Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.
    Semin Oncol. 2026;53:152518.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum